HARMONY BIOSCIENCES HLDGS IN's ticker is HRMY and the CUSIP is 413197104. A total of 60 filers reported holding HARMONY BIOSCIENCES HLDGS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,648,948 | +4.1% | 996,306 | +11.8% | 1.09% | +19.9% |
| Q2 2023 | $31,367,310 | +860.7% | 891,370 | +791.4% | 0.91% | +845.8% |
| Q1 2023 | $3,265,000 | -85.6% | 100,000 | -75.7% | 0.10% | -84.9% |
| Q4 2022 | $22,690,400 | +24.4% | 411,804 | 0.0% | 0.64% | +20.4% |
| Q3 2022 | $18,239,000 | -9.2% | 411,804 | 0.0% | 0.53% | -15.9% |
| Q2 2022 | $20,084,000 | -1.6% | 411,804 | -13.9% | 0.63% | +300.6% |
| Q4 2021 | $20,404,000 | +8.3% | 478,516 | -2.6% | 0.16% | -42.7% |
| Q3 2021 | $18,833,000 | -32.1% | 491,332 | -50.0% | 0.27% | +52.2% |
| Q2 2021 | $27,740,000 | +169.4% | 982,664 | +215.3% | 0.18% | +38.5% |
| Q1 2021 | $10,298,000 | -43.3% | 311,673 | -38.0% | 0.13% | -33.3% |
| Q4 2020 | $18,170,000 | +23.1% | 502,622 | +15.4% | 0.20% | -9.3% |
| Q3 2020 | $14,759,000 | – | 435,377 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Valor Management LLC | 11,218,033 | $478,337,000,000 | 76.20% |
| venBio Partners LLC | 2,740,411 | $116,851,000 | 21.05% |
| Vivo Capital, LLC | 4,884,341 | $208,268,000 | 12.56% |
| HealthInvest Partners AB | 195,000 | $8,315,000 | 11.72% |
| Nan Fung Group Holdings Ltd | 768,708 | $32,778,000 | 9.70% |
| Aisling Capital Management LP | 355,415 | $15,155,000 | 5.35% |
| ASHFORD CAPITAL MANAGEMENT INC | 694,783 | $29,626,000 | 2.95% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 236,000 | $10,063,000 | 2.24% |
| Newlight Partners LP | 900,824 | $38,411,000 | 2.12% |
| MPM BioImpact LLC | 142,437 | $6,074,000 | 1.11% |